Creating a vaccine to generate antibodies against HIV
Eliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based Immunogens
This study is testing a new vaccine designed to help your immune system fight HIV by targeting a specific part of the virus, and it’s for anyone interested in helping improve treatments for HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11009295 on NIH RePORTER |
What this research studies
This research focuses on developing a vaccine that targets a specific part of the HIV virus known as the fusion peptide to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs). The approach involves using a fusion immunogen made from the fusion peptide and cholera toxin subunit B, which has shown promise in animal studies for eliciting strong antibody responses. By combining this immunogen with a booster vaccine, the goal is to achieve a robust and effective immune response against various strains of HIV. If successful, this vaccine could significantly enhance the body's ability to fight HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
Not a fit: Patients who are not at risk for HIV or those who are already receiving effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides effective protection against HIV.
How similar studies have performed: Previous studies using similar immunogen approaches have shown promising results in animal models, indicating potential for success in human trials.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Kong, Xiangpeng — New York University School of Medicine
- Study coordinator: Kong, Xiangpeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.